NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma - Wikidata - awgldk - TriplyDB

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

http://www.wikidata.org/entity/Q34170552

about

New perspectives in glioblastoma antiangiogenic therapy Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.Tumor cells switch to mitochondrial oxidative phosphorylation under radiation via mTOR-mediated hexokinase II inhibition--a Warburg-reversing effect A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.Influence of autophagy on the efficacy of radiotherapy.Autophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer.MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)Targeting the PI3K/AKT/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo.Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.New Insights into Protein Kinase B/Akt Signaling: Role of Localized Akt Activation and Compartment-Specific Target Proteins for the Cellular Radiation Response.NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma.Expression profiling analysis of autophagy-related genes in perineural invasion of cutaneous squamous cell carcinoma.

P2860

Q26746028-C55D4903-90DB-4141-9F92-4F3B9F28AA56 Q26777016-81105C01-38C6-4AD4-A3CB-D5C351131BB3 Q28834576-95EECFB3-14E0-4F94-A7F4-72554F872CA4 Q34957243-6D5599E9-A073-43B5-B9B9-40E542907DF9 Q35217017-6B2FF4B2-D827-42EE-8CD2-7EB010FE9A12 Q35238420-BA210FB8-C27E-4FA8-897A-FDE95852475F Q35551953-1DA42175-2F80-4E78-8FA1-FA7EE4393D7C Q35741623-77639FB5-50BC-465D-AC2B-CB9A44E3B026 Q35751948-BB1AE8A7-0A74-43E0-BF85-66EB97A48DDA Q36544764-CA2A3BDC-8582-4354-AA24-05981E78CD3E Q37713509-4F70AF8C-FB67-4AF5-B980-7417BA531D9E Q38868651-494443A7-90B2-439A-8FD9-DAA8B7F9C41C Q41471129-D1156E8A-E3D7-41F8-B105-9A5B8F004459 Q42093380-BD7FB7B7-89B4-47A9-94DC-9D8B146CBCCF Q49451574-70C5380E-631E-4F9F-BB2B-340E954BC3DB Q52644526-8E770168-AB54-43B2-8337-28EE06581658 Q52657087-DEB4AAFB-180D-4122-B7BD-9E7A5EE73724 Q54120670-9543783F-A536-449B-A1B8-D65DD1C5D816

P2860

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

http://www.wikidata.org/entity/Q34170552

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@ast

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@en

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@nl

type

label

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@ast

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@en

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@nl

prefLabel

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@ast

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@en

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@nl

P1433

Q34170552-9D866D3E-3A30-47F9-952C-9E70E5125604

P1476

Q34170552-AA724C08-4463-4287-8747-18E853DBE14A

P2093

Q34170552-35AFE7AF-6866-476B-8B17-C78CD0CB43A8

Q34170552-5DFF6CAC-858A-4E43-9E5B-516167FFB29C

Q34170552-7A143474-20D2-4D88-8122-ADC7FD5335C7

Q34170552-B9902152-158E-4C4B-803A-4591A7A8978A

P2860

Q34170552-03179E70-1AC6-48A9-A196-776507A7D5B0

Q34170552-17075F87-4110-49F6-8976-13C6967E0691

Q34170552-1C0F78FB-1B4E-4428-9EA5-3AAFF4C43CB0

Q34170552-1F06936C-B504-4DFB-8D71-83B59183D5C8

Q34170552-36131362-882C-45C1-B061-84A7BB52E125

Q34170552-428D54D8-2C70-45A8-A8AB-079BE35E18BB

Q34170552-56DBCC26-BDF6-405C-83B6-08587909FE51

Q34170552-58DD39EB-ED0A-45AC-9E21-E1AE3EA1C1C6

Q34170552-61A18CFB-C002-41CD-B7CB-2DFCB73B5226

Q34170552-726D2273-9641-4809-9BC7-E75A98BEBE97

P304

Q34170552-CFB1917C-9D0A-4B12-9E27-7766CBAA5117

P31

Q34170552-789FAB86-4774-4FC8-A573-1DF746E10F72

P356

Q34170552-29CCE295-4318-40B0-9477-E8AA46F09210

P433

Q34170552-4BB3F0BA-F1AD-46AC-8291-5DDE6EDA3940

P478

Q34170552-0C36ACD3-550C-4A1A-96FA-B6BFDE276973

P577

Q34170552-C7C1F7F9-9142-4D64-999A-62EB08A1422C

P698

Q34170552-57A2A306-24A3-4289-B2E6-3573B903E73A

P932

Q34170552-C176225A-783F-4C0F-9D1D-F7823B95AB0C

P356

GENESANDCANCER.27

P1433

P1476

NVP-BEZ-235 enhances radiosens ...... non-small cell lung carcinoma

@en

P2093

Bo Lu

http://www.w3.org/2001/XMLSchema#string

Carey J Myers

http://www.w3.org/2001/XMLSchema#string

Dae Kwang Jung

http://www.w3.org/2001/XMLSchema#string

Kwang Woon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

High frequency of mutations of the PIK3CA gene in human cancers

Targeting phosphoinositide 3-kinase: moving towards therapy

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Cancer statistics, 2009

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.

The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.

P304

293-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/GENESANDCANCER.27

http://www.w3.org/2001/XMLSchema#string

P433

7-8

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25221647

http://www.w3.org/2001/XMLSchema#string

P932

4162139

http://www.w3.org/2001/XMLSchema#string